Sagimet Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Sagimet Biosciences Series
SGMT Stock   5.15  0.10  1.90%   
Analyzing historical trends in various income statement and balance sheet accounts from Sagimet Biosciences' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sagimet Biosciences' valuation are summarized below:
Market Capitalization
170.7 M
Enterprise Value Revenue
0.2759
Earnings Share
(1.78)
There are currently one hundred eleven fundamental trend indicators for Sagimet Biosciences Series that can be evaluated and compared over time across competition. All traders should double-check Sagimet Biosciences' current fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 303.3 M in 2026, whereas Enterprise Value is likely to drop slightly above 71.4 M in 2026.
Check Sagimet Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sagimet Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 10.7 M, Interest Income of 10.7 M or Depreciation And Amortization of 18.8 M, as well as many indicators such as Price To Sales Ratio of 39.45, Dividend Yield of 0.0 or PTB Ratio of 0.86. Sagimet financial statements analysis is a perfect complement when working with Sagimet Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Sagimet Stock
Check out the analysis of Sagimet Biosciences Correlation against competitors.

Sagimet Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets193.5 M184.3 M53.4 M
Slightly volatile
Short and Long Term Debt Total66.7 K70.2 K262.3 K
Slightly volatile
Other Current Liabilities2.9 M3.4 M1.7 M
Slightly volatile
Total Current Liabilities4 M5.1 M2.9 M
Slightly volatile
Property Plant And Equipment Net65.8 K69.3 K247.8 K
Slightly volatile
Accounts Payable955 K1.6 M1.1 M
Pretty Stable
Cash52.6 M87.2 M30.5 M
Slightly volatile
Non Current Assets Total9 M8.6 M1.7 M
Slightly volatile
Non Currrent Assets Other8.9 M8.5 M1.9 M
Slightly volatile
Other Assets21.6 K24.3 K26.5 K
Slightly volatile
Cash And Short Term Investments182.6 M173.9 M50.7 M
Slightly volatile
Common Stock Shares Outstanding25.3 M36.1 M23.5 M
Slightly volatile
Liabilities And Stockholders Equity193.5 M184.3 M53.4 M
Slightly volatile
Capital Lease Obligations66.7 K70.2 K262.3 K
Slightly volatile
Other Current Assets1.2 M1.8 M860.2 K
Slightly volatile
Other Stockholder Equity544.4 M518.5 M132.7 M
Slightly volatile
Total Liabilities3.8 M4 M119.1 M
Slightly volatile
Property Plant And Equipment Gross65.8 K69.3 K247.8 K
Slightly volatile
Total Current Assets184.5 M175.7 M51.6 M
Slightly volatile
Capital Stock3.6 K3.5 K1.5 K
Slightly volatile
Net Working Capital179.1 M170.6 M48.6 M
Slightly volatile
Short Term Debt90 K70.2 K118 K
Slightly volatile
Common Stock3.6 K3.5 K1.5 K
Slightly volatile
Property Plant Equipment204.8 K174.6 K266.4 K
Slightly volatile
Current Deferred Revenue3.2 M5.9 M2.1 M
Slightly volatile

Sagimet Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income10.7 M10.2 M1.9 M
Slightly volatile
Interest Income10.7 M10.2 M2 M
Slightly volatile
Depreciation And Amortization18.8 M35.4 M10.1 M
Slightly volatile
Selling General Administrative19.3 M18.4 M8.2 M
Slightly volatile
Other Operating Expenses65.8 M62.6 M24.9 M
Slightly volatile
Research Development46.4 M44.2 M16.8 M
Slightly volatile
Cost Of Revenue130.9 K149.5 K106.4 K
Slightly volatile
Total Operating Expenses65.8 M62.6 M24.9 M
Slightly volatile

Sagimet Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.3 M6.1 M3.2 M
Slightly volatile
Begin Period Cash Flow90.7 M86.4 M24.2 M
Slightly volatile
Depreciation107 K149.5 K53.8 K
Slightly volatile
End Period Cash Flow52.6 M87.2 M30.5 M
Slightly volatile
Change To Netincome1.6 M791.1 K2.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.4544.3848.4379
Slightly volatile
Stock Based Compensation To Revenue2.02.252.4515
Slightly volatile
EV To Sales9.4210.5911.5629
Slightly volatile
Payables Turnover0.05870.06610.0721
Slightly volatile
Sales General And Administrative To Revenue5.185.836.3666
Slightly volatile
Research And Ddevelopement To Revenue7.918.99.714
Slightly volatile
Cash Per Share2.354.341.6736
Slightly volatile
Days Payables Outstanding4 K4.5 K4.9 K
Slightly volatile
Income Quality0.690.840.7835
Slightly volatile
Current Ratio16.3830.8712.7636
Slightly volatile
Revenue Per Share0.0880.09890.108
Slightly volatile
Interest Debt Per Share0.00270.00290.0135
Slightly volatile
Debt To Assets5.0E-46.0E-40.019
Slightly volatile
Days Of Payables Outstanding4 K4.5 K4.9 K
Slightly volatile
Ebt Per Ebit1.060.960.9909
Slightly volatile
Quick Ratio16.3830.8712.7636
Slightly volatile
Cash Ratio17.3319.5810.3334
Slightly volatile
Fixed Asset Turnover21.9224.6626.9141
Slightly volatile
Debt Ratio5.0E-46.0E-40.019
Slightly volatile
Price Sales Ratio39.4544.3848.4379
Slightly volatile
Asset Turnover0.01660.01860.0203
Slightly volatile

Sagimet Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap303.3 M162.2 M311.9 M
Slightly volatile
Enterprise Value71.4 M75.1 M271.2 M
Slightly volatile

Sagimet Fundamental Market Drivers

Sagimet Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sagimet Biosciences Financial Statements

Sagimet Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Sagimet Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Sagimet Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sagimet Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.9 M3.2 M
Cost Of Revenue149.5 K130.9 K
Stock Based Compensation To Revenue 2.25  2.00 
Sales General And Administrative To Revenue 5.83  5.18 
Research And Ddevelopement To Revenue 8.90  7.91 
Revenue Per Share 0.10  0.09 
Ebit Per Revenue(13.83)(14.52)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sagimet Stock Analysis

When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY